Grail 1st-Mover Advantage Faces Regulatory Hurdles in Multi-Cancer Detection, Morgan Stanley Says
GRAIL Analyst Ratings
Morgan Stanley Initiates GRAIL at Equalweight With $16 Price Target
Balanced Risk/Reward Scenario: Hold Rating for GRAIL Inc Amid Regulatory and Financial Challenges
Grail Initiated With an Equal Weight at Morgan Stanley
Institutional Investors in GRAIL, Inc. (NASDAQ:GRAL) Have Had a Wonderful Week After Share Price Increased 12%
Golden Grail Beverages Cancels Convertible Debt to Reduce Dilution
Grail Insider Sold Shares Worth $426,937, According to a Recent SEC Filing
GRAIL to Participate in Upcoming Investor Conferences
Golden Grail Beverages CEO Shares Global Vision in New Interview With SmallCapVoice.com
Grail Tests First Patient for TROPION-Lung12 Phase 3 Study
Express News | Grail Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Wolfe Research Initiates Grail(GRAL.US) With Hold Rating
Wolfe Starts Grail at Peer Perform on Time and Money Needs
Grail Initiated With a Peer Perform at Wolfe Research
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript Summary
Express News | Sessa Capital (Master), L.p. Reports 9.66% Passive Stake in Grail as of Sept 30 - SEC Filing
GRAIL Inc (GRAL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
Golden Grail Beverages Corp. (OTC: GOGY) Retains SmallCapVoice.com Inc.